HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2019)... ... April 26, 2019 , ... ... on Thursday, April 25. More than 30 student venture teams, representing nearly 150 ... more than $75,000. , The top five teams in the College League ...
(Date:4/25/2019)... ... April 24, 2019 , ... NDA Partners Chairman Carl Peck, MD ... of experience in the development of drug and genomic diagnostic products for therapeutic indications ... joining NDA Partners, Dr. Maddala served as Vice President of Biometrics at GRAIL, Inc., ...
(Date:4/18/2019)... , ... April 18, 2019 , ... ... trials have emerged as a popular trial design that have the potential to ... been fully adopted by many sponsors due to the complexity of regulations, potential ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... Utah and BOSTON (PRWEB) , ... April 08, ... ... delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of ... integration to an unprecedented range of business and contact-orientated applications while using CT ...
(Date:4/8/2019)... Zealand (PRWEB) , ... April 09, 2019 , ... ... infectious disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has ... study of antibody repertoires is part of CZ Biohub’s efforts to establish new ...
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, an exclusive event ... today announces its Boston CEO conference to be held May 28-29, 2019 at ... opportunities with high-level panels and discussions from past, present and future change-makers. ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field of Regenerative Veterinary ... the United States and Canada since 2004. The primary indications for VetStem Regenerative ... in the dog, cat, and horse. Recently, VetStem teamed up with the world-renowned ...
Breaking Biology Technology:
Cached News: